Lux Biosciences

Lux Biosciences is a biotechnology firm focused on developing and providing health and wellness solutions through innovative bioengineering and nutraceuticals, catering to diverse consumer health needs. Founded in 2005 in Jersey City, US, Lux Biosciences specializes in biotechnology solutions. The company has executed a total of 5 deals and recently raised USD 50. 00 mn in a SERIES B funding round from investors including HBM Partners, Novo Holdings A/S, Prospect Venture Partners, and SV Health Investors.

The total amount raised by Lux Biosciences is USD 50. 00 mn with a current valuation of USD 103. 02 mn. Lux Biosciences offers a wide array of nutraceuticals and wellness supplements, aiming to enhance physical health and overall quality of life.

Their products address specific health issues, including immune support, cognitive enhancement, and metabolic health, primarily distributed across North America and Europe. The company emphasizes the rigorous scientific methods behind their formulations to ensure product safety and reliability. Lux Biosciences earns revenue through direct-to-consumer sales and partnerships with health and wellness retailers. Their flagship products are available for purchase via online platforms or through retail outlets, with a pricing structure promoting accessibility.

Additionally, the company supports its revenue model through subscription services, ensuring customer retention and loyalty. Lux Biosciences has recently ceased operations and is no longer pursuing future growth plans.